{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975667",
  "id": "02975667",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwygggfj5k9.pdf",
  "summary": "- **Revenue milestone**: Annual sales reached **AUD 208 million** (first time exceeding AUD 200 million).  \n- **Geographic expansion**: Launched Maxigesic IV/tablet (as Combogesic) in **North America** (US and Canada), with a combined addressable market of **over USD 8 billion**.  \n- **R&D pipeline**: Eight patented products in development, including migraine treatments and 24 off-patent injectables; five programs nearing commercialization (e.g., Maxigesic variants, Crystaderm).  \n- **Financials**: Net debt reduced to **AUD 14.5 million** (from AUD 16.2 million); dividend increased to **1.8 cents/share** (from 1.6 cents).  \n- **FY27 target**: Revenue goal of **AUD 300 million**, supported by market expansion.  \n\n*Omitted: Governance updates, board changes, and non-material operational commentary.*",
  "usage": {
    "prompt_tokens": 1984,
    "completion_tokens": 200,
    "total_tokens": 2184,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T21:33:28.952185"
}